**BIOGA & ALIRA HEALTH: SUPPORT PROGRAM FOR SMEs IN MARKET ACCESS**

**Introduction –** Alira Health ([www.alirahealth.com](http://www.alirahealth.com/)) is an experienced global consulting firm whose mission is to enable healthcare transformation through a wide range of services across the product lifecycle. These services include product development, regulatory, clinical, market access, management consulting, real-world evidence, transaction advisory, advanced analytics, and patient engagement. Alira’s Global Market Access team have recently entered into a collaboration with Organization X and this program is part of this collaboration.

|  |
| --- |
| **PROGRAM OVERVIEW** |
| The program offers support from an experienced team of Market Access consultants to guide companies in enhancing their value proposition, navigating the P&R ecosystem and in appropriately defining their market access needs and ambitions. The program includes a 40-hour package of service including an initial meeting, background analysis, guidance session for funding requests, application reviews and  additional consultations. The program is open for 3 SME’s and participants are selected through a  competitive process. |

|  |  |  |  |
| --- | --- | --- | --- |
| **PROGRAM BASIC INFORMATION** | | | |
| **When** | 2024/2025 | **Language** | English/ Spanish |
| **Duration** | 4 weeks/ Company | **Application** | September-October 2024 |
| **Time Schedule** | 2h/ week (day TBD1) | **Price** | Free of charge |

*1Alira will dedicate a package of 40 hours to support the Company. This package includes hours of weekly meetings and working sessions on a date agreed.*

|  |
| --- |
| **ELIGIBILITY CRITERIA** |
| This support program is eligible for **companies that are**:   * MedTech, pharma or biotech Small-Medium Enterprises (SMEs) * Members of Bioga and Iberobio (the life sciences and healthcare innovation ecosystem in Galicia, Castilla y León, Extremadura, Andalucía and Portugal, meaning the group of companies, research groups and bodies, hospitals, universities, administrations, researchers and entrepreneurs, innovation and knowledgetransfer support structures working in Galicia, Castilla y León, Extremadura, Andalucía and Portugal in this strategic sector) * Willing to pursue reimbursement/financing for a medical device, IVDR, digital solution or a drug * Currently seeking funding for market access activities |

|  |
| --- |
| **SELECTION PROCESS** |
| A board of GMA directors within Alira Health will select the companies based on:   * Calendar and dates of the funding sources according to each applicant interests * Innovation * Positive economic impact in the healthcare system * Impact in the impatient/outpatient management * Territorial scope   If the number of applicants meeting the selection criteria is higher than 3, a **5-minute pitch** might be necessary as part of the application process |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **APPLICATION FORM** | | | | | | | |
| **Company** | | | | **Applicant** | | | |
| **Name:** | | | | **Name:** | | | |
| **CIF:** | | | | **Position:** | | | |
| **Country (HQ):** | | | | **Email:** | | | |
| **Founded (year):** | | | | **Number:** | | | |
| **Address:** | | | |  | | | |
| **Number of employees:** | | | |  | | | |
| **How would you classify your company?** | | | | | | | |
| o **Medtech** | | | o **IVDR** | | o **Digital** | | |
| o **Pharma** | | | o **BioTech** | | o **Other:** | | |
| **Product in scope for this project** | | | | | | | |
| **Name:** | | | | | | | |
| **Description:** | | | | | | | |
| **Value proposition:** | | | | | | | |
| **Has your product received marketing authorization?** | | | | | | | |
| o **Yes, from the EMA** | | | | o **Yes, from FDA** | | | |
| o **Yes, I have CE mark** | | | | o **Yes, from other agencies** | | | |
| o **Not yet** | | | | | | | |
| **Current funding** | | | | | | | |
| o **<50 K** | o **50 -100 K** | | o **100 -250 K** | o **250 -500 K** | o **0.5 – 1M** | | o **>1M** |
| **Comment (optional):** | | | | | | | |
| **Target funding** | | | | | | | |
| **Funding sources of interest:** | | | | | | | |
| **Available dates of application:** *(more than one option can be selected)* | | | | | | | |
| o **Mar. 2024** | | o **Apr. 2024** | | o **May. 2024** | | o **Jun. 2024** | |
| o **Jul. 2024** | | o **Aug. 2024** | | o **Sep. 2024** | | o **Oct. 2024** | |
| **Primary Target countries for reimbursement/financing:** | | | | | | | |

|  |  |  |
| --- | --- | --- |
| o **National (Spain)** | o **EU41 + UK** | o **Other** |
| **Additional remarks** | | |
|  | | |

1Germany, France, Italy and Spain